Serine

Occurrence

This compound is one of the proteinogenic amino acids. Only the L-stereoisomer appears naturally in proteins. It is not essential to the human diet, since it is synthesized in the body from other metabolites, including glycine. Serine was first obtained from silk protein, a particularly rich source, in 1865 by Emil Cramer. Its name is derived from the Latin for silk, sericum. Serine's structure was established in 1902.

Biosynthesis

The biosynthesis of serine starts with the oxidation of 3-phosphoglycerate (an intermediate from glycolysis) to 3-phosphohydroxypyruvate and NADH by phosphoglycerate dehydrogenase (). Reductive amination (transamination) of this ketone by phosphoserine transaminase () yields 3-phosphoserine (O-phosphoserine) which is hydrolyzed to serine by phosphoserine phosphatase ().

In bacteria such as E. coli these enzymes are encoded by the genes serA (EC 1.1.1.95), serC (EC 2.6.1.52), and serB (EC 3.1.3.3).

Serine hydroxymethyltransferase (SMHT) also catalyzes the biosynthesis of glycine (retro-aldol cleavage) from serine, transferring the resulting formaldehyde synthon to 5,6,7,8-tetrahydrofolate. However, that reaction is reversible, and will convert excess glycine to serine. SHMT is a pyridoxal phosphate (PLP) dependent enzyme.

Synthesis and reactions

Industrially, L-serine is produced from glycine and methanol catalyzed by hydroxymethyltransferase.

Racemic serine can be prepared in the laboratory from methyl acrylate in several steps: :[[File:Synthesis of dl-serine.svg|class=skin-invert-image|450x450px]]

Hydrogenation of serine gives the diol serinol: :

Biological function

Metabolic

Serine is important in metabolism in that it participates in the biosynthesis of purines and pyrimidines. It is the precursor to several amino acids including glycine and cysteine, as well as tryptophan in bacteria. It is also the precursor to numerous other metabolites, including sphingolipids and folate, which is the principal donor of one-carbon fragments in biosynthesis.

Signaling

D-Serine, synthesized in neurons by serine racemase from L-serine (its enantiomer), serves as a neuromodulator by coactivating NMDA receptors, making them able to open if they then also bind glutamate. D-serine is a potent agonist at the glycine site (NR1) of canonical diheteromeric NMDA receptors. For the receptor to open, glutamate and either glycine or D-serine must bind to it; in addition a pore blocker must not be bound (e.g. Mg2+ or Zn2+). Some research has shown that D-serine is a more potent agonist at the NMDAR glycine site than glycine itself. However, D-serine has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors through the glycine binding site on the GluN3 subunit.

Ligands

D-serine was thought to exist only in bacteria until relatively recently; it was the second D amino acid discovered to naturally exist in humans, present as a signaling molecule in the brain, soon after the discovery of D-aspartate. Had D amino acids been discovered in humans sooner, the glycine site on the NMDA receptor might instead be named the D-serine site. Outside the central nervous system, D-serine plays a signaling role in peripheral tissues and organs such as cartilage, kidney, and corpus cavernosum.

Gustatory sensation

Pure D-serine is an off-white crystalline powder with a very faint musty aroma. D-Serine is sweet with an additional minor sour taste at medium and high concentrations.

Clinical significance

Serine deficiency disorders are rare defects in the biosynthesis of the amino acid L-serine. At present three disorders have been reported:

• 3-phosphoglycerate dehydrogenase deficiency
• 3-phosphoserine phosphatase deficiency
• Phosphoserine aminotransferase deficiency

These enzyme defects lead to severe neurological symptoms such as congenital microcephaly and severe psychomotor retardation and in addition, in patients with 3-phosphoglycerate dehydrogenase deficiency to intractable seizures. These symptoms respond to a variable degree to treatment with L-serine, sometimes combined with glycine. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype/phenotype correlation and outcome of these diseases their impact on the quality of life of patients, as well as for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD).

Besides disruption of serine biosynthesis, its transport may also become disrupted. One example is spastic tetraplegia, thin corpus callosum, and progressive microcephaly, a disease caused by mutations that affect the function of the neutral amino acid transporter A.

Research for therapeutic use

The classification of L-serine as a non-essential amino acid has come to be considered as conditional, since vertebrates such as humans cannot always synthesize optimal quantities over entire lifespans. Safety of L-serine has been demonstrated in an FDA-approved human phase I clinical trial with Amyotrophic Lateral Sclerosis, ALS, patients (ClinicalTrials.gov identifier: NCT01835782), but treatment of ALS symptoms has yet to be shown. A 2011 meta-analysis found adjunctive sarcosine to have a medium effect size for negative and total symptoms of schizophrenia. There also is evidence that L‐serine could acquire a therapeutic role in diabetes.

D-Serine is being studied in rodents as a potential treatment for schizophrenia. D-Serine also has been described as a potential biomarker for early Alzheimer's disease (AD) diagnosis, due to a relatively high concentration of it in the cerebrospinal fluid of probable AD patients. D-serine, which is made in the brain, has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors mitigating neuron loss in an animal model of temporal lobe epilepsy.

D-Serine has been theorized as a potential treatment for sensorineural hearing disorders such as hearing loss and tinnitus.

References

References

1. (1981). "CRC Handbook of Chemistry and Physics". CRC Press.
2. Dawson, R.M.C., et al., ''Data for Biochemical Research'', Oxford, Clarendon Press, 1959.
3. (1983). "Nomenclature and Symbolism for Amino Acids and Peptides". IUPAC-IUB Joint Commission on Biochemical Nomenclature.
4. {{IUPAC-IUB amino acids 1983.
5. (1865). "Ueber die Bestandtheile der Seide". Journal für praktische Chemie.
6. (1902). "Synthese des Serins, der ''l''-Glucosaminsäure und anderer Oxyaminosäuren". Berichte der Deutschen Chemischen Gesellschaft.
7. "Serine". encyclopedia.com.
8. (1988). "Biochemistry". W.H. Freeman.
9. KEGG [http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.3 EC 3.1.3.3] etc.
10. Uniprot: [https://www.uniprot.org/uniprot/P0AGB0 serB]
11. (2000). "Principles of Biochemistry". W. H. Freeman.
12. {{Ullmann. Karlheinz Drauz, Ian Grayson, Axel Kleemann, Hans-Peter Krimmer, Wolfgang Leuchtenberger, Christoph Weckbecker. (2006)
13. (1940). "''dl''-Serine". [[Organic Syntheses.
14. (2001). "NMDA and glycine regulate the affinity of the Mg2+-block site in NR1-1a/NR2A NMDA receptor channels expressed in Xenopus oocytes". Life Sciences.
15. (6 February 2019). "D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?". Frontiers in Psychiatry.
16. (9 June 2020). "D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders". Translational Psychiatry.
17. (2012-10-11). "Triheteromeric N-methyl-D-aspartate receptors differentiate synaptic inputs onto pyramidal neurons in somatosensory cortex: involvement of the GluN3A subunit". Neuroscience.
18. (2023-11-01). "The t-N-methyl-d-aspartate receptor: Making the case for d-Serine to be considered its inverse co-agonist". Neuropharmacology.
19. (Apr 2000). "D-Serine is an endogenous ligand for the glycine site of the ''N''-methyl-D-aspartate receptor". Proceedings of the National Academy of Sciences of the United States of America.
20. (May 2008). "Serine racemase suppresses chondrogenic differentiation in cartilage in a Sox9-dependent manner". Journal of Cellular Physiology.
21. (Nov 2008). "Mechanosensitive ''N''-methyl-D-aspartate receptors contribute to sensory activation in the rat renal pelvis". Hypertension.
22. (Jun 2010). "D-Serine modulates neurogenic relaxation in rat corpus cavernosum". Biochemical Pharmacology.
23. (Dec 2012). "Gustatory sensation of L- and D-amino acids in humans". Amino Acids.
24. de Koning TJ. (April 2006). "Treatment with amino acids in serine deficiency disorders". [[Journal of Inherited Metabolic Disease]].
25. (March 2010). "L-Serine synthesis in the central nervous system: a review on serine deficiency disorders". [[Mol Genet Metab]].
26. "Patient registry".
27. (2017). "L-Serine: a Naturally-Occurring Amino Acid with Therapeutic Potential". Neurotoxicity Research.
28. (2013). "The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation". PLOS ONE.
29. (2017-01-02). "Phase I clinical trial of safety of L-serine for ALS patients". Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
30. (Oct 2011). "Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia". CNS Drugs.
31. (2019). "L-serine: a neglected amino acid with a potential therapeutic role in diabetes". APMIS.
32. (Jun 2013). "Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction". Proceedings of the National Academy of Sciences of the United States of America.
33. (May 5, 2015). "D-Serine levels in Alzheimer's disease: implications for novel biomarker development". Translational Psychiatry.
34. (2020-10-02). "D-serine mitigates cell loss associated with temporal lobe epilepsy". Nature Communications.
35. (17 December 2021). "Physiopathological Relevance of D-Serine in the Mammalian Cochlea". Frontiers Media SA.